Ayahuasca and Mental Health: 2022–2026 Clinical Evidence Review
A 2026 integrative review synthesizes recent primary studies on ayahuasca’s associations with mental health outcomes, highlighting efficacy signals, safety risks, and the field’s methodological limitations.
Recent Evidence: Ayahuasca Linked to Mental Health Outcomes, But Causality Unproven
A 2026 integrative review (OpenAlex W7226011244) synthesizes 22 primary studies published between 2022 and 2026, examining ayahuasca’s effects on mental health. The review finds that observational studies report associations between ayahuasca use and reductions in depressive and anxiety symptoms, as well as improvements in stress and well-being. However, the review emphasizes that these findings are based on uncontrolled designs, meaning causality cannot be established. No randomized controlled trials (RCTs) meeting inclusion criteria were identified, and the studies varied widely in their methodologies, populations, and outcome measures.
Mechanisms and Research Context: Heterogeneity and Methodological Gaps
Ayahuasca is a traditional Amazonian brew containing N,N-dimethyltryptamine (DMT) and β-carbolines such as harmine, which together produce potent psychoactive effects. The review notes that most studies to date have been observational, often conducted in ceremonial or retreat settings, and use self-report measures of mental health. This heterogeneity in study populations, settings, and assessment tools limits the ability to compare results or pool data for meta-analysis. Notably, the review highlights that some studies included ayahuasca analogues or related compounds, further complicating interpretation.
One non-obvious insight is that the lack of standardized dosing and preparation methods for ayahuasca across studies introduces a significant confounder, making it difficult to attribute observed effects to the substance itself rather than to set, setting, or cultural context. This variability is rarely addressed in policy discussions but is critical for interpreting the literature.
Policy and Research Implications: No Basis for Standard Treatment
The current evidence base does not support ayahuasca as a standard treatment for any mental health disorder. The review underscores that, despite promising associations, the absence of RCTs and the predominance of uncontrolled designs preclude regulatory approval or clinical guideline inclusion in any jurisdiction. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA) require robust, controlled evidence of efficacy and safety before considering any psychedelic for therapeutic use.
For researchers, the review calls for rigorously designed clinical trials with standardized preparations, clear inclusion/exclusion criteria, and validated outcome measures. For policymakers, the findings reinforce the need for caution in expanding access or decriminalization efforts before safety and efficacy are established. For clinicians and operators, the review cautions against promoting ayahuasca as a treatment outside of approved research protocols.
Risks, Safety, and Unknowns: Acute Effects and Adverse Experiences
Ayahuasca use is associated with acute physical effects, most commonly nausea and vomiting, as well as transient increases in blood pressure and heart rate. The review documents adverse psychological experiences in some participants, including anxiety, confusion, and, in rare cases, persistent psychological distress. The lack of systematic follow-up in most studies means that long-term safety remains poorly characterized.
Furthermore, the review notes that most studies excluded individuals with a history of psychosis or severe mental illness, so the risks for these populations are unknown. The potential for drug-drug interactions, particularly with antidepressants and other serotonergic agents, is another area of concern that is insufficiently addressed in the current literature.
Outlook: The Path Forward for Ayahuasca Research
Future progress in ayahuasca research depends on addressing methodological shortcomings and prioritizing participant safety. The field would benefit from multi-site RCTs with standardized ayahuasca preparations, rigorous safety monitoring, and long-term follow-up. Collaboration between academic researchers, Indigenous communities, and regulatory agencies will be essential to ensure that research protocols are both scientifically sound and culturally respectful.
Until such evidence is available, ayahuasca should not be considered a standard or approved intervention for mental health conditions. The review’s findings highlight the importance of skepticism and scientific rigor in evaluating emerging psychedelic therapies.
By Dr. Mariana Alves, MD, PhD (psychiatry, Universidade de São Paulo). Reviewed by Dr. Rafael Torres, MD, MPH on 2026-11-14. Research based on primary sources and OpenAlex W7226011244.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.